Status:
UNKNOWN
Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial
Lead Sponsor:
Nanchang University
Conditions:
Proteinuria
HBVe-antigen
Eligibility:
All Genders
18-60 years
Brief Summary
Lamivudine treatment for HBV-DNA negative HBV-GN patients.
Detailed Description
lamivudine and predinisone treatment for HBV-DNA negative HBV-GN patients.
Eligibility Criteria
Inclusion
- Adult HBV-GN patients with biopsy-proven MN, heavy protinuria, HBsAg or HBeAg positive, HBV-DNA negative
Exclusion
- Primary MN patients, HBV-DNA positive
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01152060
Start Date
January 1 2010
End Date
November 1 2010
Last Update
June 29 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.